stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) Return on assets
Medpace Holdings, Inc.'s return on assets over the twelve months to 30 September 2026 was 25.5%, up 3.4 percentage points from fiscal 2025 (22.1%). Over the past ten years it has ranged from −0.83% (fiscal 2015) to 22.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 22.1% | 0.61 |
| FY2024 | 21.5% | 2.72 |
| FY2023 | 18.8% | 2.51 |
| FY2022 | 16.3% | 4.37 |
| FY2021 | 11.9% | 0.48 |
| FY2020 | 11.4% | 1.95 |
| FY2019 | 9.49% | 1.89 |
| FY2018 | 7.60% | 3.55 |
| FY2017 | 4.05% | 2.68 |
| FY2016 | 1.37% | 2.20 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| MEDP Medpace Holdings, Inc. | 25.5% |
| ILMN Illumina, Inc. compare | 13.8% |
| QGEN QIAGEN N.V. compare | 6.99% |
| DGX Quest Diagnostics Incorporated compare | 6.73% |
| LH Labcorp Holdings Inc. compare | 5.40% |
| ICLR ICON PLC compare | 2.74% |
| RVTY Revvity Inc. compare | 2.14% |
| CRL Charles River Laboratories International, Inc. compare | 0.54% |
| GH Guardant Health, Inc. compare | −30.7% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement